|
Multiple Myeloma
|
|
Smouldering
|
Ithaca (SMM)
Phase 3 randomized, open label, multicenter study of Isatuximab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
|
Open to recruitment
|
|
Newly Diagnosed
|
GSK2857916 DREAMM 9 (ND MM)
A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation
|
Open to recruitment
|
|
IRiL (ND MM)
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma
|
Open to recruitment
|
|
ALLG MM22 / FRAIL-M (ND MM)
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study
|
Pending to Open
|
|
ALLG MM23 SeaLAND (ND MM)
An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma
|
Open to recruitment
|
|
Relapsed Refractory
|
AbbVie M15-654 (R/R MM)
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
|
Open to recruitment
|
|
AMaRC 19-02 BelaCarD (R/R MM)
A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma.
|
Open to recruitment
|
|
AMG701 ParadigMM-1B (R/R MM)
A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
Pending to open
|
|
BGB-11417-105 (R/R MM)
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in
Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
|
Pending to open
|
|
CC-220-MM-002 EXCALIBER (R/R MM)
A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab And Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, And Dexamethasone (Dvd) In Subjects With Relapsed Or Refractory Multiple Myeloma
|
Pending to open
|
|
Celgene CC-92480-MM-001 (R/R MM)
A Phase 1 Multicenter, Open-Label Study To Assess The Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
|
Open to recruitment
|
|
GSK2857916 DREAMM 3 (R/R MM)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma
|
Open to recruitment
|
|
GSK2857916 DREAMM 5 (R/R MM)
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) in Combination with Anti- Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma
|
Open to recruitment
|
|
GSK207497 DREAMM 6 (R/R MM)
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma
|
Open to recruitment
|
|
GSK2857916 DREAMM 8 (R/R MM)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma
|
Open to recruitment
|
|
Janssen 64007957MMY1004 MajesTEC-2
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma
|
Open to recruitment
|
|
Pfizer MAGNETISMM-3
An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Elranatamab (Pf-06863135) Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody
|
Open to recruitment
|
|
Acute Myeloid Leukaemia & Myelodysplastic Syndrome
|
|
Treatment
Naïve
Newly diagnosed
|
ALLG AML M23 (HOVON) (TN AML, TN MDS)
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
|
Open to Recruitment
|
|
ALLG AML M25 (INTERVENE) (ND AML)
An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia
|
Open to Recruitment
|
|
M15-954 (Verona) (ND MDS)
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
|
Open to recruitment
|
|
KER050-MD-201 (ND MDS)
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
|
Open to recruitment
|
|
Relapsed Refractory
|
BGB-11417-103 (R/R Myeloid Malignancies)
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
|
Open to recruitment
|
|
Chronic Lymphocytic Leukaemia
|
|
Treatment Naïve
|
BGB3111_304 (TN CLL)
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
|
Open to recruitment
|
|
Treatment Naïve & Relapsed Refractory
|
BGB-11417-101 (TN, R/R CLL)
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
|
Open to recruitment
|
|
Relapsed Refractory
|
Assure (R/R CLL)
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic leukaemia
|
Open to Recruitment
|
|
PCYC-1145-LT (R/R CLL)
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
|
Need to be from an eligible Parent study
|
|
Chronic Myeloid Leukaemia
|
|
Treatment Naive
|
ASCEND-CML study CML13 (ND CML)
An ALLG single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia
|
Open to recruitment
|
|
Lymphomas
|
|
Treatment Naïve
|
ALLG NHL30 PETReA (TN FL)
Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
|
Open to Recruitment
|
|
BGB-3111-306 Mangrove (TN MCL)
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
|
Open to recruitment
|
|
MOR208C310 FRONTmind (TN DLBCL)
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)
|
Pending to open
|
|
Treatment Naïve &
Relapsed Refractory
|
Ascentage APG2575WU101 MAPLE-1 (TN WM, R/R WM)
A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenström Macroglobulinemia
|
Open to recruitment
|
|
Relapsed Refractory
|
ALLG NHL33 – WAMM (R/R MCL)
An ALLG Window study of Acalabrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma
|
Open to recruitment
|
|
Ascentage APG-2575-001 (R/R CLL, WM, DLBCL, AML, NHL, MCL)
A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with hematologic malignancies
|
Open to recruitment
|
|
BGB-11417-101 (R/R) B-cell NHL
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
|
Open to recruitment
|
|
BGB-3111-LTE1 (R/R DLBCL, FL, CLL, SLL, MCL)
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B Cell Malignancies
|
Need to be from an eligible Parent study
|
|
BGB-A317-210 TIRHOL (R/R cHL)
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
|
Open to recruitment
|
|
Genentech GO29781 (R/R DLBCL, FL, MZL, NHL, RT, SLL, MCL)
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic leukaemia
|
Open to recruitment
|
|
GENMAB GCT3013-01 (R/R DLBCL and FL)
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
|
Open to recruitment
|
|
GILEAD Magrolimab (R/R NHL)
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
|
Open to recruitment
|
|
IGM Biosciences IGM-2323-001 (R/R NHL)
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
|
Open to recruitment
|
|
MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies
|
Open to recruitment
|
|
Roche GO41943 (R/R DLBCL)
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of RO7082859 or Mosunetuzumab (RO7030816) in Combination with Gemcitabine plus Oxaliplatin in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
|
Open to recruitment
|
|
TG-1701-101 (R/R CLL, WM, NHL)
A Phase 1 Pharmacokinetic and Pharmacodynamics Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients with B-Cell Malignancies
|
Open to recruitment
|
|
Bleeding Disorders
|
| |
DIAAMOND (Aplastic Anaemia)
Section A: Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia - The DIAAMOND Ava-FIRST Trial
Section B: Avatrombopag iN Relapsed or Refractory severe aplastic anaemia as EXtra Therapy – The DIAAMOND Ava-NEXT Trial
|
Open to recruitment
|
|
TREATT
TREATT Trial to Evaluate Tranexamic acid therapy in Thrombocytopenia. A double blind randomized controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with hematological malignancies with severe thrombocytopenia.
|
Open to recruitment
|
|
Registries / Other
|
|
Myeloma 1000 Registry
The Myeloma 1000 Project
|
Open to recruitment
|
|
MRDR Registry
Myeloma & Related Diseases Registry
|
Open to recruitment
|
|
NBCR
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)
|
Open to recruitment
|
|
Carfilzomib Retrospective 20170766 (R/R MM)
Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific
|
Open to recruitment
|
|
C-SMART
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial
|
Pending to Open
|
|
COVID Study
A Multi-Centre National study of COVID-19 infection in Cancer patients
|
Open to recruitment
|
|
MOR208C213 (RE-MIND2) (R/R DLBCL)
An observational retrospective cohort study of systemic therapies for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), to compare outcomes to those from Tafasitamab + Lenalidomide in the L-MIND study
|
Open to recruitment
|